Topic: vaccine development
Biogen and Bayer deal with coronavirus rule-breakers in China. AbbVie's Kaletra fails COVID-19 study. Fosun licenses BioNTech's coronavirus vaccine.
CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.
Gilead's remdesivir, if effective, could scale up fast, experts said, and antibodies in development, like Regeneron's, might beat vaccines to market.
Researchers had high hopes for a HIV vaccine candidate made up of components supplied by GlaxoSmithKline and Sanofi, but it didn't work.
The U.K. government plans to enroll the world's largest clinical trial to treat COVID-19, but its health department is warning it might take time.
Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.
As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.
CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.